Boehringer Hopes To Expand Product Line, Achieve 35 Percent Growth Rate In China
This article was originally published in PharmAsia News
Executive Summary
With the addition of Sifrol (pramipexole), Spiriva (tiotropium peptide), and Micardis (telmisartan) to China's new health insurance directory, Boehringer Ingelheim became a big winner in the list's latest revision